FENC - CIK 0001211583
The table below shows FENNEC PHARMACEUTICALS INC.'s cash flow statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q1 2025 | Q1 2024 | Q1 2023 | Q2 2022 | Q1 2022 |
|---|---|---|---|---|---|---|
| Operating cash flow | $2.38M | -$4.32M | $39.05M | -$5.58M | -$3.39M | -$2.86M |
| Capital expenditure | - | - | - | - | - | - |
| Investing cash flow | - | - | - | - | - | - |
| Dividends paid | - | - | - | - | - | - |
FENNEC PHARMACEUTICALS INC. reported operating cash flow of -$12.47M for fiscal year 2025. That is down 146.2% from $26.98M in fiscal 2024. Over the 10 fiscal years shown, operating cash flow declined from -$2.12M (FY 2016) to -$12.47M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| Stock buybacks | - | - | - | - | - | - |
| Financing cash flow | $1.01M | $359.00K | -$1.13M | $193.00K | - | $15.00K |